Evaluating VERVE-102 for lowering cholesterol in specific heart disease patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and pharmacodynamic profile of VERVE-102, a gene-editing therapy designed to lower LDL cholesterol levels by disrupting the PCSK9 gene in the liver. It targets patients with heterozygous familial hypercholesterolemia or premature coronary artery disease who require additional LDL-C lowering. The study is open-label and employs a single-ascending dose approach to assess the effects of VERVE-102. Participants will be monitored for safety and efficacy throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of HeFH or premature CAD

Exclusion Criteria:

* Homozygous familial hypercholesterolemia
* Active or history of chronic liver disease
* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
* Clinically significant or abnormal laboratory values as defined by the protocol

Where it's running

• Clinical Study Center
  Dothan, Alabama, United States Recruiting
• Clinical Study Center
  Pomona, California, United States Recruiting
• Clinical Study Center
  Boca Raton, Florida, United States Recruiting
• Clinical Study Center
  Jacksonville, Florida, United States Recruiting
• Clinical Study Center
  Winter Park, Florida, United States Recruiting
• Clinical Study Center
  Indianapolis, Indiana, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-guided post-discharge care for premature coronary artery disease

  This trial will test whether an AI-powered app and stratified management system can lower deaths, heart attacks, strokes, and rehospitalizations and improve risk-factor control in adults aged 18–45 with premature coronary artery disease.

  Recruiting China National Center for Cardiovascular Diseases · Hefei, Anhui and 15 other locations · NCT07031531

• Predicting future heart problems in young adults with premature coronary artery disease (MAP-CHD)

  This project will follow Chinese adults under 45 with premature coronary artery disease to see if clinical features and blood tests can predict future adverse heart events.

  Recruiting China National Center for Cardiovascular Diseases · Beijing · NCT07004452

• Evaluating HST101 for lowering cholesterol in Chinese patients

  This study is testing if a new drug called HST101 can lower cholesterol levels in Chinese patients who have high cholesterol and are at risk for heart disease.

  Recruiting at 17 sites Phase 3 Hasten Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 17 other locations · NCT06568471

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.